Your browser doesn't support javascript.
loading
EZH2 regulates pancreatic cancer cells through E2F1, GLI1, CDK3, and Mcm4.
Li, Hongfeng; Wang, Hailong; Cui, Yunlong; Jiang, Wenhua; Zhan, Hongjie; Feng, Lixia; Gao, Mingyou; Zhao, Kuo; Zhang, Limeng; Xie, Xiaojing; Zhao, Ning; Li, Ying; Liu, Pengfei.
Afiliación
  • Li H; Department of Clinical Laboratory, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, 300120, China.
  • Wang H; Department of Oncology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, No. 354 Beima Road, Hongqiao District, Tianjin, 300120, China.
  • Cui Y; Department of Hepatobiliary Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
  • Jiang W; Department of Radiotherapy, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.
  • Zhan H; Department of Gastric Cancer, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
  • Feng L; Department of Nursing, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Konggang Hospital, Tianjin, 300300, China.
  • Gao M; Department of Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
  • Zhao K; Department of Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
  • Zhang L; Department of Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
  • Xie X; Department of Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
  • Zhao N; Department of Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
  • Li Y; Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, No. 12 Health Road, Shijiazhuang, 050000, Hebei, China. liying8000@163.com.
  • Liu P; Department of Oncology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, No. 354 Beima Road, Hongqiao District, Tianjin, 300120, China. liupengfeitj@163.com.
Hereditas ; 160(1): 23, 2023 May 17.
Article en En | MEDLINE | ID: mdl-37198697
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas Límite: Humans Idioma: En Revista: Hereditas Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas Límite: Humans Idioma: En Revista: Hereditas Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido